Lemaitre Vascular (LMAT) Sells General Surgery Product Lines for $7.4M

LeMaitre Vascular, Inc. (Nasdaq: LMAT), announced today that it has divested its general surgery product lines to Symmetry Surgical, Inc. for $7.4 million.

Included in the divestiture were the Reddick Cholangiogram Catheter and Reddick Saye-Screw, both used during laparoscopic cholecystectomy procedures. As part of the transaction, the parties entered into a two-year manufacturing transition services agreement.

Dave Roberts, LeMaitre Vascular’s President, commented, “We are pleased to divest these general surgical product lines and to rationalize our portfolio. Following this transaction, all of LeMaitre’s remaining 14 product lines are now focused on the needs of our core customer, the vascular surgeon.”

“Symmetry Surgical is excited to add the Reddick® product lines to our comprehensive laparoscopic portfolio,” says Scott Kunkel, Chief Financial Officer, Symmetry Surgical. “We look forward to partnering with LeMaitre Vascular during this transition period to provide excellent service to our customers.”

In 2017, LeMaitre’s general surgery product lines accounted for $3.3 million in revenue and $2.5 million in gross profit.

Business Outlook

LeMaitre Vascular will provide Q1 results as well as updated full year 2018 guidance on April 25, 2018.

Advisors

High Peaks Partners, LLC served as advisor to LeMaitre Vascular.

You May Also Be Interested In

• Morgan Stanley CEO: investment banking momentum is building - Conference Call
• Barrick Gold (GOLD) reported preliminary Q1 production of 940 thousand ounces of gold
• New Horizon Aircraft (HOVR) Issues Corporate Update